Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising
about
DNA repair targeted therapy: The past or future of cancer treatment?Double-strand break repair and colorectal cancer: gene variants within 3' UTRs and microRNAs binding as modulators of cancer risk and clinical outcomeNSC666715 and Its Analogs Inhibit Strand-Displacement Activity of DNA Polymerase β and Potentiate Temozolomide-Induced DNA Damage, Senescence and Apoptosis in Colorectal Cancer CellsNuclear TRADD prevents DNA damage-mediated death by facilitating non-homologous end-joining repairCellular stress responses in cancer and cancer therapy.Regulation of NEIL1 protein abundance by RAD9 is important for efficient base excision repairDNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells.Cells and Stripes: A novel quantitative photo-manipulation technique.Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formationCloning, localization and focus formation at DNA damage sites of canine Ku70.Structure-Based Virtual Ligand Screening on the XRCC4/DNA Ligase IV Interface.Role of the double-strand break repair pathway in the maintenance of genomic stability.Torin2 Suppresses Ionizing Radiation-Induced DNA Damage RepairAberrant DNA Double-strand Break Repair Threads in Breast Carcinoma: Orchestrating Genomic Insult Survival.Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents in urothelial carcinoma of the bladder.Cloning, localization and focus formation at DNA damage sites of canine XRCC4.Cloning, localization and focus formation at DNA damage sites of canine XLF.RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy.Common Chemical Inductors of Replication Stress: Focus on Cell-Based Studies.The novel role of pyrvinium in cancer therapy.The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer.Association between miRNA-binding site polymorphisms in double-strand break repair genes and risk of recurrence in patients with squamous cell carcinomas of the non-oropharynx.Genomic landscape of gastric cancer: molecular classification and potential targets.Human rpL3 plays a crucial role in cell response to nucleolar stress induced by 5-FU and L-OHP.The therapeutic landscape of HIV-1 via genome editingA lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress.Physiological Roles of DNA Double-Strand Breaks.Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer.The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy.Potential genotoxic and cytotoxicity of emamectin benzoate in human normal liver cells.Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.Monitoring DNA Repair Consequences of ATM Signaling Using Simultaneous Fluorescent Readouts.TP53 Arg72Pro polymorphism is associated with increased overall survival but not response to therapy in Portuguese/Caucasian patients with advanced cervical cancer.Rad9a is involved in chromatin decondensation and post-zygotic embryo development in mice
P2860
Q26768679-7C2D07CA-4CE2-4121-AFB5-831A97FE26F2Q28271788-F6220EE2-FCA7-4258-9D00-E773762F8708Q28546932-65480993-08C0-4A3A-8E2C-8D2AAF0F3C0AQ33794303-4CFDA90A-F43E-401D-864E-295F2F8F009FQ34419337-8C98E53A-55EA-4B8C-80E1-F38701407DA0Q35786136-02FCC345-52A2-4F79-B32B-D236785BAA83Q35881648-45064363-659E-43F5-903B-A2ECA66E7E31Q35896405-E91D70EA-4E35-498E-A1F2-59A1C98E328DQ36070463-A4069094-E01B-4D8E-B559-0E2670EF852CQ36271016-2AF7B579-8F69-48FE-B0EF-3288F289E5ACQ36674946-F1ED12D7-E244-4BF4-89B9-43A365BF9F5AQ36997781-200C2000-B091-4C64-9386-E97A5FF577A5Q37041046-7253EAAF-71D1-4689-8E56-744062AFEA04Q37552296-6E696907-B2A5-415E-AC57-54DCBDC5294EQ37564392-A2EC3A20-B680-40FC-9EB8-44B8B18E1F6FQ37590074-112E9D45-E397-47E7-9513-FF13D4EAB700Q37621309-7EC0163A-A8AB-4711-9390-5658F91F9172Q37644990-37027A96-9C92-4F86-A6FB-37B74960B7D4Q37729428-5FAD1576-34E3-4984-841B-3C0886A19F7DQ38684406-4D9481B7-F6B9-4617-B2E2-4718694F7FA7Q38690281-25FB2DED-7172-409C-BF8D-465C10261391Q38740972-AE2FC870-7ADB-426A-9E60-EE9652361183Q38837669-41640CB1-4627-44C0-80B4-B03A354736DFQ38932327-59D1FA5B-6640-41AD-ACC1-56293A65BC22Q39153976-C5A05EF0-3251-4785-83BA-32EE49327320Q41362934-85413B19-FB21-412F-80E7-A0FFCCBE6E00Q47108181-27D68290-333E-4791-838E-184F01721E83Q49544395-32E37507-4427-423C-8808-98E68CF2FB86Q50017359-B33EA136-79D6-41D1-928D-AC29142B188AQ50021065-F9C35055-0F46-4A2D-AB49-1CAB4E698AE4Q52590685-92808186-C38A-4D1D-8DD5-3F96923AC10CQ52772554-3A285D6B-BFBB-4820-BA6B-7B1249769C88Q55060818-4CAB5CB5-DCDF-4B50-A58A-CA46BC2B8282Q61948488-f3df3fb2-4279-7d8f-7eff-8c786f20d29c
P2860
Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Chemotherapeutic compounds tar ...... od, the bad, and the promising
@ast
Chemotherapeutic compounds tar ...... od, the bad, and the promising
@en
Chemotherapeutic compounds tar ...... od, the bad, and the promising
@nl
type
label
Chemotherapeutic compounds tar ...... od, the bad, and the promising
@ast
Chemotherapeutic compounds tar ...... od, the bad, and the promising
@en
Chemotherapeutic compounds tar ...... od, the bad, and the promising
@nl
prefLabel
Chemotherapeutic compounds tar ...... od, the bad, and the promising
@ast
Chemotherapeutic compounds tar ...... od, the bad, and the promising
@en
Chemotherapeutic compounds tar ...... od, the bad, and the promising
@nl
P2860
P50
P3181
P356
P1476
Chemotherapeutic compounds tar ...... od, the bad, and the promising
@en
P2093
Christian Jekimovs
Kenneth J O'Byrne
P2860
P3181
P356
10.3389/FONC.2014.00086
P407
P577
2014-04-22T00:00:00Z